SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Press releases

SK bioscience Submits Biologics License Application to the KMFDS for Novavax Covid-19 Vaccine Candidate

2021. 11. 15
SK bioscience Announces Positive Data from Phase I/II Clinical Trial of COVID-19 Vaccine Candidate

2021. 11. 05
SK bioscience and CEPI Extend Agreement Contract Production of COVID-19 Vaccines by the End of 2022

2021. 10. 06
SK bioscience Enters the Third Phase of Clinical Trial of COVID-19 Vaccine Candidate

2021. 08. 30
SK bioscience Initiates Phase III Clinical Trial of COVID-19 Vaccine Candidate with Promising Interim Data

2021. 08. 10
SK Bioscience Submits Phase III IND for COVID-19 Vaccine

2021. 06. 28
SK bioscience reinforces responsible management and establishes ESG and Human Resources Committees

2021. 06. 24
SK bioscience to Sign MOU with Andong and North Gyeongsang Province for Expansion of Factories and Sites

2021. 06. 21
CEPI Funds Reaches Up to 210.1 million USD to SK bioscience to Advance COVID-19 Vaccine Development

2021. 05. 24
SK bioscience Obtained EU-GMP (Good Manufacturing Practice) Certification of COVID-19 Vaccine Manufacturing and Quality Control

2021. 05. 17